Olanzapine as a medication to reduce nausea and vomiting following chemotherapy in childre
Phase 2
- Conditions
- Palliative care.Encounter for palliative care
- Registration Number
- IRCT20090613002027N14
- Lead Sponsor
- Sari University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Cognitive abilities of 4 years old age
Receiving chemotherapy medications with moderate to severe risk of emesis
Age between 4 to 18 years old
Exclusion Criteria
Brain tumor
Receive of any anti psychotics 30 days before enrollment
Inhibitors/Inducers of CYP1A2
History of neuroleptic malignant syndrome
History of seizure
Sensitivity to olanzapine
Cardiac arrhythmia
History of uncontrolled diabetes mellitus
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of nausea in the first 5 days after chemotherapy. Timepoint: Baseline, 1, 2, 3, 4 and 5 days after intervention. Method of measurement: Interview with the patient.;Frequency of vomiting in the first 5 days after chemotherapy. Timepoint: Baseline, 1, 2, 3, 4 and 5 days after intervention. Method of measurement: Interview with the patient.
- Secondary Outcome Measures
Name Time Method